Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.70
-0.1200-1.22%
Post-market: 9.700.00000.00%16:04 EDT
Volume:2.66M
Turnover:25.67M
Market Cap:2.48B
PE:-6.44
High:9.72
Open:9.72
Low:9.46
Close:9.82
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:1.17
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-5.46
PE(LYR):8.02

Loading ...

BioCryst announces Japan MHLW marketing approval for Orladeyo

TIPRANKS
·
Aug 25

BioCryst Says Japan Approves Orladeyo for Pediatric HAE Patients Aged 2-11

Reuters
·
Aug 25

BioCryst Announces Approval of Orladeyo® for Pediatric Hae Patients in Japan

THOMSON REUTERS
·
Aug 25

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

Simply Wall St.
·
Aug 15

BioCryst Pharmaceuticals (BCRX) Could Be 54% Undervalued Following Strong Earnings Guidance

Simply Wall St.
·
Aug 12

SIGA Technologies Q2 Revenue, Profit Drop as Contract Ends

Reuters
·
Aug 07

BioCryst Pharmaceuticals Price Target Cut to $20.00/Share from $21.00 by Wedbush

Dow Jones
·
Aug 07

Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook

Reuters
·
Aug 06

Zevra Therapeutics Q2 Revenue Rises 53% on Miplyffa Sales

Reuters
·
Aug 06

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

Reuters
·
Aug 06

Emergent BioSolutions Swings to Q2 Loss on Impairment Charge; to Cut Jobs

Reuters
·
Aug 06

Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised

MT Newswires Live
·
Aug 05

BioCryst Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

UroGen Pharma Q2 Revenue Beats on Strong Zusduri Sales

Reuters
·
Aug 05

Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.15

MT Newswires Live
·
Aug 05

BioCryst Pharma Q2 EPS $0.30, Sales $218.250M Beat $182.514M Estimate

Benzinga Earnings
·
Aug 05

BioCryst Pharmaceuticals Outlook FY Sales USD 690-715 Million

THOMSON REUTERS
·
Aug 05

BioCryst Pharmaceuticals Q2 EPS USD 0.3

THOMSON REUTERS
·
Aug 05

BioCryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash and Investments $354 Mln at June 30, 2026

THOMSON REUTERS
·
Aug 05